rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Edward M. Fitzgerald

Director

Company insider

Files Form 4 as: Director, Parabilis Medicines; Director, Akcea Therapeutics; Executive VP, Ariad Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
121
Buys
0
Sells
20
Bought
$0
Sold
$4.9M
Companies
3
Companies where not an officer
2
First trade
16 Apr 2007
Last trade
11 Jun 2026
Last filed
15 Jun 2026

Companies traded

Where they are an officer
Ariad PharmaceuticalsOfficer · last 21 Mar 20160 buys · 20 sells
Everywhere else they filed: board seats, 10% stakes, other companies
PBLS Parabilis MedicinesDirector · Biotechnology · last 11 Jun 20260 buys · 0 sells
Akcea TherapeuticsDirector · last 14 Jun 20190 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—5,539filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—3,878filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—5,271filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—5,332filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—3,666filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—8,111filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—5,332filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—3,666filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code C—8,111filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—5,539filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—3,878filing
11 Jun 2026filed 15 Jun 2026PBLS Parabilis MedicinesBiotechnologySEC FORM 4 Code C—5,271filing
9 Jun 2026filed 11 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code A—20,215 at $0.00filing
9 Jun 2026filed 11 Jun 2026PBLS Parabilis Medicinesoption or derivative · BiotechnologySEC FORM 4 Code A—20,215 at $0.00filing
14 Jun 2019filed 18 Jun 2019Akcea Therapeuticsoption or derivativeSEC FORM 4 Code A—26,400 at $0.00filing
1 Jun 2018filed 5 Jun 2018Akcea Therapeuticsoption or derivativeSEC FORM 4 Code A—26,400 at $0.00filing
21 Mar 2016filed 22 Mar 2016Ariad PharmaceuticalsSEC FORM 4 Sold$35K5,417 at $6.47filing
19 Mar 2016filed 22 Mar 2016Ariad PharmaceuticalsSEC FORM 4 Code M—10,833 at $0.00filing
19 Mar 2016filed 22 Mar 2016Ariad Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—10,833 at $0.00filing
7 Mar 2016filed 9 Mar 2016Ariad Pharmaceuticalsoption or derivativeSEC FORM 4 Code A$567K87,125 at $6.51filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed20

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.